College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Urology Unit, Austin Health, Melbourne, VIC, Australia.
BJU Int. 2024 Jun;133(6):699-708. doi: 10.1111/bju.16286. Epub 2024 Feb 26.
To explore the causes of the decrease in bladder cancer survival that has occurred over the past four decades.
We extracted data from the South Australian Cancer Registry. Data from the period 1 January 1977 to 31 December 2020 were extracted to explore changes in incidence and survival among a total of 8356 patients diagnosed with ≥pT1 disease. Invasive bladder cancer was defined as ≥pT1 in this study.
Invasive bladder cancer age-standardized incidence decreased from 7.20 cases per 100 000 people in 1977 to 5.85 cases per 100 000 in 2020. The mean age at diagnosis increased from 68 years to 76 years. The crude incidence for patients aged 80 years and over increased by 3.3% per year (95% confidence interval [CI] 2.1 to 4.6). Overall survival decreased over the study period (hazard ratio [HR] 1.22 [95% CI 1.09 to 1.35]), however, survival increased after adjusting for age at diagnosis (HR 0.80 [95% CI 0.76 to 0.94]). Despite a decrease in non-bladder cancer-specific deaths in older people, there was no change in the bladder cancer-specific death rate in older people (HR 0.94 [95% CI 0.70 to 1.26]). Male sex was associated with higher survival (HR 0.87 [95% CI 0.83 to 0.92]), whereas socioeconomic advantage was not.
Invasive bladder cancer survival has decreased over the past 40 years, with the age structure of the population being a significant contributing factor.
We looked at why bladder cancer survival is decreasing using a large cancer registry with information from 1977 to 2020. We found that people are now more likely to be diagnosed at an older age. Older people often live for a shorter time with bladder cancer compared to younger people. Bladder cancer survival has decreased because there are more older people with the disease than previously.
探讨过去四十年间膀胱癌生存率下降的原因。
我们从南澳大利亚癌症登记处提取数据。本研究共纳入了 8356 例诊断为≥pT1 疾病的患者,提取了 1977 年 1 月 1 日至 2020 年 12 月 31 日期间的数据,以探讨发病率和生存率的变化。本研究中,浸润性膀胱癌定义为≥pT1。
浸润性膀胱癌年龄标准化发病率从 1977 年的每 10 万人 7.20 例降至 2020 年的每 10 万人 5.85 例。诊断时的平均年龄从 68 岁增加到 76 岁。80 岁及以上患者的粗发病率每年增加 3.3%(95%置信区间[CI]:2.1 至 4.6)。研究期间总生存率下降(风险比[HR]1.22[95%CI:1.09 至 1.35]),但在调整诊断时的年龄后生存率增加(HR 0.80[95%CI:0.76 至 0.94])。尽管老年人中非膀胱癌特异性死亡人数减少,但老年人膀胱癌特异性死亡率没有变化(HR 0.94[95%CI:0.70 至 1.26])。男性的生存情况较好(HR 0.87[95%CI:0.83 至 0.92]),而社会经济优势则没有。
过去 40 年浸润性膀胱癌的生存率下降,人口年龄结构是一个重要的促成因素。
我们使用一个包含 1977 年至 2020 年信息的大型癌症登记处来研究为什么膀胱癌的生存率在下降。我们发现,现在人们更有可能在老年时被诊断出患有膀胱癌。与年轻人相比,老年人的膀胱癌存活时间更短。膀胱癌的生存率下降是因为现在患有这种疾病的老年人比以前多了。